Welcome to our dedicated page for BGM Group SEC filings (Ticker: BGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to BGM Group Ltd. (NASDAQ: BGM) regulatory filings once they are available, alongside AI-powered tools that help interpret complex documents. While no specific SEC filings are listed in the provided data, investors typically look to these disclosures to understand how a company like BGM reports on its biopharmaceutical operations and multi-segment AI technology activities.
For a business that combines biopharmaceutical production with AI platforms in insurance, mobility, robotics, and fintech, filings such as annual reports (Form 10-K) and quarterly reports (Form 10-Q) can be important sources of information. These documents often describe business segments, risk factors related to pharmaceuticals and AI services, and details of acquisitions and integration of entities like Rongshu Technology, Xinbao Investment Company, Wonder Dragon Global Limited, YX Management Company Ltd., HM Management Company Limited, Xingdao Intelligent, and YD Network, as referenced in company news.
When available, current reports on Form 8-K can highlight material events such as strategic transactions, leadership changes, or significant agreements related to AI insurance platforms like Du Xiao Bao and Bao Wang, or to the Duxiaobao ecosystem. Proxy statements can provide additional context on governance and the board’s role in BGM’s technological transformation.
Stock Titan’s platform is designed to pair these filings with AI-powered summaries that explain key sections in plain language, highlight notable changes, and make it easier to locate information about BGM’s AI initiatives, biopharmaceutical division, and corporate structure. As new SEC filings for BGM are posted to EDGAR, they can be surfaced here with real-time updates and contextual insights.
Group Ltd reported board and leadership changes. Effective January 27, 2026, Yuehua Ren and Lou Zefei were appointed as directors, and Li Yuqing was appointed as co-chief executive officer for one-year terms.
Ms. Ren has a digital media degree and marketing experience at biotechnology and investment firms. Ms. Lou is a senior finance executive with economics and EMBA degrees and long financial management experience. Mr. Li has led Hanzhou Yaoyixing Technology Co., Ltd. since 2021, driving development of an AI PaaS platform. The company states that none of the three has family relationships with existing directors or executives, and none has engaged in related-party transactions requiring disclosure under Regulation S-K Item 404(a).
FAQ
What is the current stock price of BGM Group (BGM)?
What is the market cap of BGM Group (BGM)?
